Literature DB >> 8671599

IgM natural antibody against an asialo-oligosaccharide, gangliotetraose (Gg4), sensitizes HIV-I infected cells for cytolysis by homologous complement.

X Wu1, N Okada, M Iwamori, H Okada.   

Abstract

Although cells are usually resistant to homologous complement, the IgM antibody against gangliotetraose (Gg4), an asialo-oligosaccharide of GM1, was found to cause cytolysis of HIV-1 infected cells by homologous complement. Due to its size, IgM might enable the initiation of the complement cascade away from membrane complement inhibitors such as decay accelerating factor and membrane cofactor protein. Furthermore, HRF20 (CD59), which restricts formation of membrane attack complexes (MAC) of complement on homologous cell membranes, was significantly decreased on HIV-infected cells and therefore formation of MAC on cell membranes would be facilitated. IgM antibodies reactive with HIV-infected cells could result in the elimination of infected cells via complement-mediated cytolysis in HIV-infected patients, since all tested sera from HIV-positive hemophilia patients who have survived for >12 years contained IgM antibody activity against HIV-infected MOLT4 cells in a preliminary experiment. Therefore, administration of IgM antibodies reactive with HIV-infected cells may be effective in the treatment of HIV carriers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671599     DOI: 10.1093/intimm/8.1.153

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  2 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  IgM colocalises with complement and C reactive protein in infarcted human myocardium.

Authors:  P A J Krijnen; C Ciurana; T Cramer; T Hazes; C J L M Meijer; C A Visser; H W M Niessen; C E Hack
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.